BCMA-GPRC5D CART

PreclinicalCell therapy

GGuangzhou Bio-gene Technology Co., Ltd

BCMA-GPRC5D CART is one of 25 small molecule programs targeting Multiple Myeloma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaActive, not recruiting

Multiple MyelomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Adriamycin

GGynecologic Oncology Group

Preclinical

9 6

Nolvadex

AstraZeneca

Preclinical

1 7

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Abecma

Bristol-Myers Squibb

Preclinical

4 10

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ANot yet recruiting

Multiple Myeloma

NCT07195617

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment

Not yet recruiting·GGuangzhou Bio-gene Technology Co., Ltd·N/A·NCT07195617·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BCMA-GPRC5D CART. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BCMA-GPRC5D CART compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BCMA-GPRC5D CART. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou Bio-gene Technology Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: GGuangzhou Bio-gene Technology Co., Ltd

BCMA-GPRC5D CART

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News